Very exciting news from the FDA highlights the recent accelerated approval of mosunetuzumab-axgb, Genentech’s full-length bispecific monoclonal antibody that targets the B cell–specific surface antigen CD20 and the T cell surface protein CD3, for adults with relapsed or refractory follicular lymphoma. Find the article here (https://www.nature.com/articles/d41591-023-00010-0).
This is a riveting article highlighting the merit of neoadjuvant immunotherapy over systemic chemotherapy for patients with operable non small cell lung cancer. This is a very interesting question because several trials have suggested that the addition of immune checkpoint inhibitors (ICIs) conferred impressive superior event-free survival (EFS) and a pathological response. Find the article here (https://jamanetwork.com/journals/jamaoncology/article-abstract/2800945).
Patient that received definitive treatment for head and neck cancer typically receive radiation therapy with concurrent cisplatin unless ineligible. This typically leads to poorer clinical outcomes with the omission of systemic therapy. This article published by JCO demonstrates that the addition of docetaxel concurrent to definitive head and neck radiation for cisplatin-ineligible patients significantly prolongs survival at the cost of more mucosal toxicity. Very exciting result. Find the article here (https://ascopubs.org/doi/full/10.1200/JCO.22.00980).
Interesting article highlighting factors associated with the carcinogenesis and clinical outcomes associated with African-Americans and Prostate Cancer. This commentary is a must read. Find the article here (https://ascopubs.org/doi/10.1200/JCO.22.02203).
This article attempted to question whether or not the introduction of immune checkpoint inhibitors (ICIs) changed survival in younger vs older patients with non–small cell lung cancer (NSCLC). In this cohort study of 53 719 adults with NSCLC, ICIs disseminated rapidly into clinical practice across all age groups after US Food and Drug Administration approval. However, there were differential implications for survival: patients younger than 55 years experienced clinically meaningful survival gains, whereas patients 75 years or older did not. Find the article here (https://jamanetwork.com/journals/jamaoncology/article-abstract/2800947).
In the field of Radiation Oncology, dose maximums are typically confined by nearby organs at risk (OARs). However we try to explore dose escalation in many setting with the thought that it may lead to better tumor control. This multi-center trial tested two personalised radiotherapy dose-escalation strategies in 107 patients with stage II/III lung cancer. Freedom from local failure rates were high (1-year > 90%) in both arms though unexpected increased rates of grade 5 events were seen in both arms. Find the article here (https://www.sciencedirect.com/science/article/pii/S0167814023000300).
When we think about modulation of the immune system in biologics we typically think about enhancing the immune system through checkpoint blockade, notably in oncology. For instance anti-PD1 antibodies have revolutionized the landscape of tumor immunotherapy. On the contrary this article highlights a PD-1 agonist antibody suppressed inflammation in murine disease models, indicating its clinical potential for treatment of various inflammatory disorders, including autoimmune diseases. Find the article here (https://www.science.org/doi/10.1126/sciimmunol.add4947).
This is an interesting perspective article that highlights how some of the elderly patient population navigates the diagnosis of cancer alone. Imagine the toll that it takes on you individuals on a emotional and physical level when navigating this alone. Find the perspective here (https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2800827).
Diffuse intrinsic pontine glioma (DIPG) remains a fatal brainstem tumor demanding innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) tumors, investigators opened BrainChild-03 (NCT04185038), a first-in-human phase I trial administering repeated locoregional B7-H3 CAR T cells to children with recurrent/refractory CNS tumors and DIPG. This is the first report of repeatedly dosed intracranial B7-H3 CAR T cells for patients with DIPG and includes preliminary tolerability, the detection of CAR T cells in the CSF, CSF cytokine elevations supporting locoregional immune activation, and the feasibility of serial mass spectrometry from both serum and CSF. Find the article here (https://aacrjournals.org/cancerdiscovery/article/13/1/114/712703/Intraventricular-B7-H3-CAR-T-Cells-for-Diffuse).
Many meningiomas harbor inactivating mutations in NF2. Cells deficient in the protein merlin (which is the product of NF2) are susceptible to inhibition of focal adhesion kinase (FAK). In the setting of FAK inhibition, NF2 mutated cells have disruption of their adhesions to the extracellular matrix and other cells. The objective of this study was to evaluate the efficacy of focal adhesion kinase (FAK) inhibition in meningiomas, as part of the national genomically driven phase II study in meningiomas. It showed that FAK inhibition with GSK2256098 resulted in an improved 6-month progression-free survival compared with historical controls in patients with meningiomas harboring somatic alterations in NF2. Furthermore, treatment with GSK2256098 was well tolerated, with no grade 4 or 5 events. Find the article here (https://ascopubs.org/doi/abs/10.1200/jco.21.02371).
For Stage III NSCLC we are always looking for ways to increase treatment outcomes. One question that has been posed is does the inclusion of ipilimumab (anti CTLA-4 therapy) improve the response to concurrent chemoradiation for stage III NSCLC? Patients were treated with 60 Gy in 30 fractions and one of three platinum doublet chemo regimens. Ipilimumab was given on week 1 and 4 of treatment. After completing CRT, 12 cycles of maintenance nivolumab were administered. The trial was stopped early after enrolling just 19 patients largely due to a high rate (42%) of grade 3+ pulmonary toxicity. Find the article here (https://www.redjournal.org/article/S0360-3016(23)00046-9/fulltext).
Internal mammary node irradiation (IMNI) is a perpetual subject of discussion in the adjuvant treatment of early breast cancer. The treatment increases heart radiation dose, and long-term side effects might outweigh benefits. In the Danish Breast Cancer Group Internal Mammary Node study, using a unique pragmatic study design, allocation to IMNI was based on cancer laterality: Patients with right-sided cancer received the treatment, whereas patients with left-sided cancer did not. With a 15-year follow-up, IMNI decreased the risk of distant recurrence and death from breast cancer, thereby improving long-term overall survival. Find the article here (https://ascopubs.org/doi/abs/10.1200/JCO.22.00044).
The optimal strategy for dealing with locally advanced rectal cancer is often debated. One option includes a total neoadjuvant therapy (TNT) strategy comprising hypofractionated radiation (5 Gy × 5) followed by chemotherapy. The STELLAR trial evaluated whether this TNT approach is noninferior to standard chemoradiotherapy (CRT) in this patient population. This study demonstrates noninferiority for the primary end point, 3-year disease-free survival, in patients receiving TNT versus standard CRT (64.5% v 62.3%, respectively; P < .001 for noninferiority). Find the article here (https://ascopubs.org/doi/full/10.1200/JCO.21.01667).
New research at Massachusetts General Hospital indicates that cancer radiation therapy causes the skin to produce the hormone β-endorphin, and that elevated β-endorphin levels contribute to fatigue after treatment. Blocking β-endorphin prevented fatigue-like behavior in radiation-treated animals. This is important as the radiation induced fatigue can lead to discontinuation and delay in several treatment regiments. Find the article here (https://www.science.org/doi/10.1126/sciadv.abn6025).
It was not long ago and it continues to remain an option, that definitive therapy for intact prostate radiation therapy was consistently completed in over 7+ weeks. The PACE-B trial evaluated conventionally fractionated radiotherapy (control RT) with five fractions of stereotactic body RT (SBRT) in patients with localized prostate cancer. This article highlights the 2-year toxicity results of the phase 3 PACE-B trial. Although the results highlight the overall good tolerance of ultra-hypofractionation, the higher cumulative incidence of moderate GU toxicity observed in patients administered the five-fraction SBRT schedule merits some consideration. Find the correspondence article here (https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00615-5/fulltext).
讨论圈